CSL and HUB24: Two ASX Stocks With Different Growth Profiles

CSL and HUB24 sit on opposite ends of the ASX growth spectrum. One is a mature biotech with a 1.5% dividend yield and a 14.6% return on equity. The other is a wealth management platform growing revenue at 44% a year. Both attract Australian investors, but for very different reasons.

CSL operates through three divisions. CSL Behring handles blood plasma products. CSL Seqirus makes flu vaccines and provides pandemic services to governments. CSL Vifor focuses on iron deficiency and kidney care. The company reported a debt-to-equity ratio of 62.8% in FY24, meaning it carries more equity than debt. Its average dividend yield over five years sits at 1.5%. ROE came in at 14.6%, above the 10% threshold analysts often look for in mature businesses.

For income-focused investors, the yield is low but consistent. For those tracking total return, the ROE suggests the company generates decent profit from shareholder equity. The debt level is manageable. None of these numbers alone tell the full story, but they offer a starting point for valuing CSL shares.

HUB24 tells a different story. The company provides software for financial advisers, super funds, and accountants. Its three main products are the HUB24 platform, Class, and myprosperity. The HUB24 platform gives advisers access to managed funds and investment products. Class helps self-managed super funds handle portfolios, legal docs, and compliance. Myprosperity targets accountants and advisers who want to improve client service.

Revenue grew at a compound rate of 44.4% per year over three years, hitting $328 million in FY24. Net profit rose from $10 million to $47 million over the same period. ROE was 9.2%, lower than CSL's, but that reflects the company's reinvestment phase. Growth companies often show lower ROE early because they plow earnings back into the business.

HUB24 won the Overall Best Platform award in the 2024 Adviser Ratings Financial Advice Landscape Report. It also ranked first for Overall Satisfaction and Brand Image in the 2024 Wealth Insights Platform Service Level Report. Those awards point to a competitive advantage in service quality, which matters in a market where advisers and clients can switch platforms easily.

The two stocks suit different portfolio goals. CSL offers steady income and a proven business model in a growing healthcare sector. HUB24 offers faster growth but at a higher valuation and with less history of dividend payouts. Neither is a clear buy or sell based on these metrics alone. The next step is valuation work: comparing price to earnings, cash flow, and peers.

For those interested in a deeper dive, the CSL stock page shows the company's valuation history and recent news. Broader stock market analysis can help put both stocks in context with the broader ASX.

Both companies face risks. CSL depends on plasma collection costs and regulatory approvals for new drugs. HUB24 faces competition from other wealth platforms such as Netwealth and Praemium. A slowdown in the wealth management industry or a shift in adviser preferences could hit HUB24's growth rate. For CSL, a weakening in the plasma market or a failed drug trial would pressure the stock.

Investors should look at the full picture before making a decision. These metrics are a starting point, not a conclusion.